NPI 1013480979: Open Payments
NPI 1013480979. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,564 in 81 payments from 9 companies in 2025. Trend: 2023 $444 · 2024 $253 · 2025 $1,564
Food & beverage: $1,341Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $410 |
| Vanda Pharmaceuticals Inc. | 13 | $314 |
| ABBVIE INC. | 14 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $168 |
| Janssen Pharmaceuticals, Inc | 10 | $166 |
| E.R. Squibb & Sons, L.L.C. | 10 | $139 |
| Neurocrine BioSciences, Inc. | 5 | $113 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 1 | $24 |
Products named: FANAPT, VRAYLAR, CAPLYTA, COBENFY, AUSTEDO XR, INGREZZA, INVEGA SUSTENNA, HETLIOZ.
